Ironshore Pharmaceuticals & Development Inc. and Children and Adults with Attention-Deficit/Hyperactivity Disorder (CHADD) recently made an agreement for Ironshore to sponsor programs that raise awareness of the impact of ADHD during the early morning routine (EMR).
Ironshore, a wholly owned subsidiary of Highland Therapeutics Inc., will finance the advocacy programs that will inform teachers, parents and doctors about the effects of ADHD during the EMR. With this sponsorship, CHADD will be able to create three individual webinars to offer educational material; it will post these webinars online in October for ADHD Awareness Month.
Various functional problems present themselves to ADHD patients during their EMR, which can create sustaining impacts during the rest of the day. This is why it is important for all parents, teachers and doctors to understand ADHD during the EMR and how it can affect ADHD patients throughout the rest of the day.
“We recognize Ironshore’s sponsorship of these outreach initiatives as consistent with our mission to improve the lives of people affected by ADHD,” April Gower, CHADD’s chief operations officer, said. “Early morning functional impairments represent an unmet medical need in the treatment of ADHD, and we are delighted to be bringing awareness to this important issue. We are particularly pleased to mark ADHD Awareness Month by developing new resources for the many families with ADHD that we serve.”
